Full-Time

Cloud Software Engineer 2

Abbott

Abbott

10,001+ employees

Global healthcare company manufacturing medical devices

No salary listed

Mumbai, Maharashtra, India

In Person

Category
Software Engineering (1)
Required Skills
Software Testing

Get referred to Abbott

See people who can refer or advise you

Requirements
  • High School Diploma / GED
  • Minimum 1 year experience
Responsibilities
  • Develops more complex design for a unit, code and test by working independently, applying standards, and yet adapting precedent to make departures from established processes to resolve problems.
  • Documents the work as per standards and may guide more junior colleagues on how to follow established procedures.
  • Help build a robust module meeting more complex design specifications.

Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lake Bluff, Illinois

Founded

1888

Get referred to Abbott

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cologuard drives mid-teens growth, adding $3.1B cancer diagnostics revenue in 2026.
  • 2026 EPS guidance raised to $5.45–$5.60, signaling confidence in MedTech pivot.
  • 54-year dividend increase streak reinforces S&P 500 Dividend Aristocrat status with $0.63 quarterly payout.

What critics are saying

  • ShinyHunters breached Cancer Diagnostics via vishing, stealing 30M+ PII rows and 1M+ SSNs in June 2026.
  • DOJ dropped criminal probe into Sturgis baby formula plant linked to 9 infant deaths after Trump's $500K stock buy.
  • Nutrition segment declined 3.1% in Q2 2026, threatening margin expansion if MedTech pivot stalls.

What makes Abbott unique

  • Abbott uniquely combines high-margin MedTech with cancer diagnostics via $21.5B Exact Sciences deal.
  • FreeStyle Libre dominates CGM market with 11% Q2 2026 sales jump to $2.19B.
  • Heart device franchise remains resilient amid elective procedure pressures due to electrophysiology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Professional Development Budget

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

16%
UAE News 24/7
Jul 27th, 2026
M42 and Abbott enhance UAE's cancer screening abilities.

M42 and Abbott enhance UAE's cancer screening abilities. M42's National Reference Laboratory and Abbott Partner to Advance Early Cancer Detection Capabilities in the UAE * Combining global healthcare innovation with national diagnostic expertise will support earlier detection, informed clinical decision-making and improved patient outcomes * Partnership supports the UAE's vision to enhance early detection and preventive healthcare capabilities Abu Dhabi, UAE - July23, 2026:M42's National Reference Laboratory (NRL), a leading provider of diagnostic services in the region hasentered into a strategic partnership with Abbottto support the introduction of innovative early cancer detection solutions in the UAE, usingadvanced diagnostic solutions based on biomarker testing and multi-marker algorithm-driven analysesto strengthen the country's diagnostic capabilities and support earlier, more informed clinical decision-making. As part of the agreement, NRL and Abbott will work together to implement innovative early cancer detection solutions designed to support earlier identification of cancer and more informed clinical decision-making. The initial phase will focus on a pilot programme aimed at reducing cancer incidence and mortality while improving patient outcomes across the UAE, ahead of broader implementation, helping establish the foundations for wider adoption across the healthcare ecosystem. The partnership marks a significant step in advancing access to innovative diagnostic technologies in the UAE, where the Ministry of Health and Prevention has identified early detection and screening as critical components of the UAE's National Cancer Control Programme. Guided by the UAE Vision 2031 agenda, these efforts are designed to help close gaps in the current system, strengthen the country's oncology ecosystem, and position the UAE as a regional benchmark for equitable, high-quality cancer care. Dr. Laila Abdel Wareth, Chief Executive Officer of National Reference Laboratory, said: "At NRL, we are committed to advancing diagnostic excellence and bringing innovative healthcare solutions to the communities we serve. This partnership with Abbott reflects our shared ambition to strengthen early cancer detection capabilities in the UAE by enabling access to cutting-edge diagnostic technologies. By combining Abbott's global expertise with NRL's role as the UAE's leading reference laboratory, we aim to support earlier diagnosis, empower clinicians with actionable insights and ultimately improve patient outcomes." As part of the agreement, NRL and Abbott will work together to implement innovative early cancer detection solutions designed to support earlier identification of cancer and informed clinical decision-making. The initial phase will focus on a pilot program ahead of broader implementation, helping establish the foundations for wider adoption across the healthcare ecosystem. Omar Riyal, Divisional Vice President for Abbott's cancer diagnostics business - International Commercial Operations, said: "What matters most is the impact on patients. Together with NRL Uaenews247 is advancingearlier detection andsupporting better clinical decision-making, reinforcing its shared commitment to elevate standards of care in the UAE. The partnership brings together the complementary strengths of two leaders in healthcare innovation. Abbott is a global healthcare leader with more than 135 years of experience, offering a broad portfolio of life-changing technologies across diagnostics, medical devices, nutritionals and branded generic medicines. NRL serves as a national reference laboratory and plays a critical role in advancing diagnostic capabilities and healthcare innovation across the UAE.Through this collaboration, both organizations aim to support the evolution of precision diagnostics and contribute to a healthcare system where earlier detection can help improve outcomes for patients across the country. About National Reference Laboratory National Reference Laboratory (NRL), part of M42, is a leading diagnostic services provider in the UAE, offering a comprehensive range of laboratory testing and clinical diagnostic solutions. Serving a wide network of hospitals, clinics and healthcare providers, NRL plays a central role in enabling accurate, timely diagnosis and supporting improved patient outcomes. With a focus on innovation, quality and operational excellence, NRL leverages advanced technologies and specialised expertise to deliver high-quality diagnostic services, supporting the evolution of precision and personalised medicine across the region. M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combinesits specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers, including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi. For media inquiries or interview opportunities, please contact: Mazar Masud Senior Director, Global Corporate Communications, M42 M: +971 52 593 5926 Asala Fadda Senior Manager, Marketing & Communications, M42 M: +971 509555076

CaseValue.Law
Jul 24th, 2026
Abbott spinal cord stimulator lawsuit: 17 patients sue.

Abbott spinal cord stimulator lawsuit: 17 patients sue. 17 patients sued Abbott over defective spinal cord stimulators. Learn about your rights and use its calculator to estimate your potential case value today. Case Value Expert July 24, 2026 Abbott Laboratories faces joint suit over spine implants. Seventeen patients have recently joined forces to file a product liability lawsuit against Abbott Laboratories, alleging that the company's spinal cord stimulators (SCS) are defective and dangerous. These devices, designed to manage chronic pain by delivering electrical pulses to the spine, supposedly malfunctioned, causing severe internal injuries and worsening the very conditions they were meant to treat. According to recent reports, the plaintiffs claim that the manufacturer failed to ensure the safety and efficacy of these complex medical implants. This joint action highlights a growing concern regarding the reliability of neurostimulation technology in the medical field. Victims across the country are now looking for answers as more complications come to light regarding these specific Abbott models. Professional legal guidance is essential when dealing with such high-stakes medical device failures. Affected by a product liability issue? Its specialized tool can help you estimate the potential worth of your case based on current laws and precedents. Establishing fault in medical device failure claims. Determining fault in medical device litigation often centers on whether a product was designed poorly, manufactured with defects, or sold with inadequate warnings. In this Abbott case, the liability may extend beyond simple hardware failure to include the company's failure to warn patients and physicians about known risks associated with the stimulators. Lawyers are investigating whether the company prioritized profit over patient safety by rushing these devices to market without sufficient long-term testing. Additionally, legal theories of strict liability may apply, where the manufacturer is held responsible for a defective product regardless of intent or specific negligence during the production phase. The involvement of multiple patients suggests a systemic issue rather than isolated incidents, strengthening the argument for corporate negligence and long-term liability. Crucial steps for victims of faulty spinal implants. If you or a loved one has suffered complications from a spinal cord stimulator, the first priority is seeking immediate medical evaluation to document any physical harm or device migration. It is crucial to preserve all medical records related to the implantation surgery and any subsequent revision procedures required to fix or remove the device. You should also consult with legal experts who specialize in medical device failure and legal options. This follows recent concerns regarding unlicensed Abbott representatives and other complications in calculating your potential case value. To get an initial idea of what your claim might be worth, you can use its free case calculator to estimate the potential value of your recovery. Early documentation and professional guidance are the best ways to protect your rights against large medical corporations. Potential compensation and settlement tiers for SCS injuries. Compensation in medical device lawsuits typically covers a wide range of economic and non-economic damages caused by the faulty implant. Victims may be entitled to recover the costs of original surgeries, expensive revision procedures, and ongoing physical therapy needed to manage pain or mobility issues. Beyond medical bills, settlement values often account for lost wages if the injury prevented the victim from working, as well as significant awards for pain, suffering, and emotional distress. Factors such as the age of the victim and the permanency of the injury play a major role in determining the final settlement amount. In cases where a company is found to have acted with gross negligence, punitive damages might also be awarded to punish the firm and deter future misconduct. Understanding the product liability legal framework. Product liability claims for medical devices are governed by a complex mix of state laws and federal regulations overseen by the Food and Drug Administration (FDA). Most states follow a strict liability standard, meaning a plaintiff must prove the device was defective and that the defect directly caused their injuries. It is also important to understand the legal standards for products liability which define how manufacturers must ensure their products are safe for intended use. Patients must be mindful of the statute of limitations, which varies by state but generally provides a limited window of time to file a claim after the injury is discovered. Navigating these rules requires a deep understanding of both professional malpractice standards and the specific protocols for mass tort litigation. Evaluate your Abbott spinal stimulator claim today. Navigating a lawsuit against a multi-billion dollar company like Abbott is a daunting task, but you do not have to face it alone. Its team is dedicated to helping injury victims understand the true value of their claims through expert analysis and comprehensive legal resources. By using its tools, you can move past the confusion and take a concrete step toward securing the compensation you deserve for your medical bills and suffering. Whether your injury occurred in a hospital or was the result of a long-term device malfunction, CaseValue provide the clarity needed to pursue justice. Try its product liability case calculator today to see how your specific circumstances translate into a potential legal recovery. Disclaimer: This blog post is for informational purposes only and does not constitute legal advice. For specific legal guidance regarding your situation, please consult with a qualified attorney.

ISMG Corp
Jul 24th, 2026
Patient sues Abbott Labs, Exact Sciences in Data Theft.

Patient sues Abbott Labs, Exact Sciences in Data Theft. Class Action Suit Claims Labs Failed to Safeguard Data in ShinyHunters Hack Marianne Kolbasuk McGee (HealthInfoSec) - July 24, 2026 The first of what could be many more proposed class action lawsuits has been filed in a U.S. federal court against clinical testing laboratory and medical device maker Abbott Laboratories and its cancer diagnostics business Exact Sciences in the wake of a data theft hack claimed last week by notorious cybercrime gang ShinyHunters. The lawsuit filed in an Illinois federal court alleges, among other claims, that the Illinois-based Abbott and its Exact Sciences business - which provides cancer screenings, diagnostic testing, and related laboratory services to patients and healthcare providers in the United States - failed to implement "necessary data security safeguards" to protect the plaintiff's and class members' sensitive personal and health information from unauthorized access and theft by cybercriminals. "The data breach and the injuries it caused to plaintiff and class members occurred as direct, proximate and foreseeable results of multiple failings on the part of defendants," alleges the lawsuit filed on Wednesday by Brian Troesch - a patient of Exact Sciences, on behalf of himself and other individuals similar situated. "This failure resulted in cybercriminals accessing the private information of defendants' current and former patients." The lawsuit is seeking monetary damages as well as injunctive relief requiring Abbott and Exact Sciences to strengthen their data security systems and monitoring procedures and conduct periodic audits of those IT systems. In addition, the lawsuit wants Abbott to provide "lifetime credit monitoring and identity theft insurance to plaintiff and class members." Abbott Labs in a July 16 statement posted on its website acknowledged it's investigating a breach involving its Exact Sciences business. Abbott said the incident appears to involve unauthorized access to a limited number of internal systems in the company's Cancer Diagnostics business only (see: Craneware, Abbott Probe Separate Health Data Theft Incidents). "This does not impact any business operations, product or product availability, manufacturing or lab operations, or our ability to serve patients," the company said. "There is no impact to any other Abbott businesses, sites or systems. The legacy Exact Sciences systems are separate from Abbott's." But the Exact Sciences incident is not the only alleged hack Abbott confirmed it's investigating. The company in a statement to ISMG on Monday acknowledged that the company is also investigating claims that another threat actor gained access to Abbott's LabCentral portal. Cybercrime gang ShadowByt3$ claimed to media outlet Bleeping Computer this week to have exfiltrated an array of manufacturing certificates, operation manuals, technical specifications, regulatory documentation, product requirement archives, calibrator value assignments, assay files and other product documentation related to Abbott's laboratory diagnostic systems. ShinyHunters on its dark website on Friday still listed "Abbott-owned Exact Sciences" as a victim, indicating that it had extended until July 21 its threat for the company to "pay or leak." "We have made an extension to your deadline. We are issuing one last final warning due to the severity of this case. You wouldn't want us to describe what was exfiltrated from you publicly," ShinyHunters wrote. As of Friday, which was three days after that supposed final deadline, ShinyHunters had appeared to not yet begin leaking Abbott's data. Abbott on Friday declined further comment to ISMG on either cyber incident, ShinyHunter's latest threats or the proposed class action lawsuit filed by Troesch.

CyberUpdates365
Jul 19th, 2026
Abbott data breach: ShinyHunters claims theft of 30 million patient records.

Abbott data breach: ShinyHunters claims theft of 30 million patient records. Healthcare giant Abbott Laboratories is investigating two separate cyber incidents this week, after the notorious extortion gang ShinyHunters claimed to have stolen tens of millions of records from the company's Cancer Diagnostics business. This Abbott cyber attack, now widely tracked as the ShinyHunters Abbott incident, has drawn significant attention due to the scale of records the group claims to have taken. A second, unrelated group is also claiming a separate breach of Abbott's LabCentral customer portal. Abbott has confirmed unauthorized access occurred, but disputes the scale of what attackers claim to have taken, and says the incidents have not disrupted patient care, manufacturing, or business operations. Table of Contents What ShinyHunters claims to have stolen. ShinyHunters told security outlet BleepingComputer that it broke into Abbott's systems through a vishing (voice phishing) attack targeting several employees in mid-June. The group claims this let it compromise a corporate Microsoft Entra single sign-on (SSO) account, which in turn gave it access to data across connected platforms including Salesforce, Microsoft 365, Google Workspace, SAP, ServiceNow, SharePoint, Databricks, and Coupa. According to the group's claims, the haul includes more than 30 million rows of customer personal data - names, emails, phone numbers, physical addresses, dates of birth, and over 1 million Social Security numbers. ShinyHunters further claims to have taken more than 22 million client notes containing doctor-patient conversations, over 20 million medical orders, plus internal contracts and NDAs. It's important to stress that none of this stolen data has actually been published, and researchers have not independently verified the scale of what the group claims. ShinyHunters added Abbott to its dark web extortion site, initially threatening to leak the data after July 18, before extending the deadline to July 21. Abbott's official response on the Exact Sciences breach. In an official statement, Abbott confirmed unauthorized access to a limited number of internal systems within its Cancer Diagnostics business specifically. This Abbott Exact Sciences breach involves legacy infrastructure inherited through the company's March 2026 acquisition of Exact Sciences, maker of the Cologuard and Cancerguard screening tests. Abbott says this legacy environment is separate from its core systems, and that the incident has not impacted product availability, manufacturing, lab operations, or patient care. Abbott says it activated its incident response plan, engaged outside cybersecurity experts, and notified law enforcement. The company also stated it does not currently expect the incident to have a material impact on its financial results. A second, separate claim: the LabCentral portal. A different threat actor, using the name ShadowByt3$, separately claims to have breached Abbott's Core Laboratory diagnostics business through its LabCentral customer portal, allegedly using compromised customer credentials to exploit what it described as a weak point in the environment starting July 4, 2026. This group claims to have taken manufacturing certificates, operating manuals, technical specifications, and regulatory documentation - but says no customer data was involved. Abbott disputes the significance of this claim entirely, stating that LabCentral is an externally hosted portal containing only publicly available reference documents, not sensitive business or customer information. Why ShinyHunters keeps targeting healthcare companies. This is far from ShinyHunters' first attack on the medtech sector. The group has run a sustained campaign since last year specifically targeting employees' Microsoft Entra, Okta, and Google SSO accounts through social engineering, and has previously been linked to breaches at Medtronic, OneMedical, AdaptHealth, iRhythm, and device maker Stryker - the latter targeted just after it recovered from a separate destructive attack. Healthcare and medtech companies remain attractive targets because a single compromised employee SSO login can act as a master key to dozens of connected SaaS platforms holding sensitive patient and business data - often without triggering the kind of alarms a direct network intrusion would. How to protect against vishing-based SSO attacks. Since this attack chain relies on tricking employees over the phone rather than exploiting software bugs, defenses need to focus on identity and process: * Enforce phishing-resistant MFA on SSO: FIDO2 hardware keys or platform authenticators can't be relayed over a phone call the way an SMS or voice-read OTP code can. * Verify help-desk reset requests out-of-band: Many vishing attacks target IT help desks directly, impersonating employees to request password or MFA resets - require a secondary verification channel before any reset. * Monitor SaaS app access patterns: A compromised SSO account often shows unusual login locations or bulk data exports across connected apps like Salesforce or SharePoint - anomaly detection here can catch attacks in progress. * Segment legacy acquired systems: As seen here, systems inherited through acquisitions (like Exact Sciences) are common weak points - audit and isolate them promptly rather than leaving them loosely connected to core infrastructure. Frequently asked questions. Was I affected by the Abbott data breach? If you've had contact with Abbott's Cancer Diagnostics or Exact Sciences business - as a patient, customer, or through doctor-patient notes - your data may be among what ShinyHunters claims to have stolen, though this remains unverified and unpublished at this time. Who is ShinyHunters? ShinyHunters is an extortion gang that has run a sustained campaign since 2025 targeting corporate SSO accounts (Microsoft Entra, Okta, Google) through social engineering, previously linked to breaches at Medtronic, iRhythm, Stryker, and 7-Eleven. Has Abbott confirmed the full scope of the breach? Abbott has confirmed unauthorized access to a limited number of internal Cancer Diagnostics systems but has not confirmed the scale of data ShinyHunters claims to have stolen, which remains unverified by independent researchers. Is Abbott's LabCentral portal breach serious? Abbott disputes this separately claimed incident's significance, stating the LabCentral portal only contains publicly available technical documents, not sensitive customer or business data. Reported by CyberUpdates365 desk. Delivering the latest insights on enterprise security, federal AI directives, and the future of IT infrastructure. Follow Cyber Updates 365 for daily updates on how technology is reshaping the corporate landscape. * Uday Patil Cybersecurity Expert | DevOps Engineer Founder and lead author at CyberUpdates365. Specializing in DevSecOps, cloud security, and threat intelligence. My mission is to make cybersecurity knowledge accessible through practical, easy-to-implement guidance. Strong believer in continuous learning and community-driven security awareness.

Bulletproof Servers
Jul 18th, 2026
Abbott Laboratories probes two cyber incidents amid extortion claims

Abbott Laboratories probes two cyber incidents amid extortion claims. Abbott Laboratories is investigating two separate cybersecurity incidents after confirming unauthorized access to internal legacy Exact Sciences systems in its Cancer Diagnostics business, while also investigating a separate claim that attackers breached its LabCentral portal and stole company data. The company confirmed the Cancer Diagnostics incident after the ShinyHunters extortion gang added Abbott to its data leak site, initially threatening to publish allegedly stolen data after July 18 unless the company negotiated with the group, before later extending the deadline to July 21. When BleepingComputer asked Abbott about the alleged ShinyHunters incident, Abbott directed BleepingComputer to a statement published on its website. "Abbott is investigating a cyber incident in which there was unauthorized access to a limited number of internal systems in our Cancer Diagnostics business only," the company said. "This does not impact any business operations, product or product availability, manufacturing or lab operations, or our ability to serve patients." Abbott added that the security incident has not impacted any other Abbott businesses or systems, and said the legacy Exact Sciences systems are separate from Abbott's. The company said it activated its incident response procedures after it learned of the incident, engaged cybersecurity experts, and notified law enforcement. Abbott also stated that it does not expect the incident to have a material impact on its business or financial results. ShinyHunters claimed to BleepingComputer that it gained access through a vishing attack targeting several Abbott employees in mid-June. According to the threat actor, the attack allowed it to compromise a Microsoft Entra single sign-on (SSO) account and gain access to internal systems. Since last year, the extortion group has been conducting social engineering campaigns that target employees' Microsoft Entra, Okta, and Google SSO accounts. After gaining access to a corporate SSO account, the threat actors steal data from connected SaaS applications such as Salesforce, Microsoft 365, Google Workspace, SAP, Slack, Adobe, Atlassian, Zendesk, Dropbox, and many others. The extortion gang has been increasingly targeting medtech companies, including Medtronic, OneMedical, and AdaptHealth. BleepingComputer has learned that ShinyHunters was also behind the iRhythm data breach and targeted Stryker soon after the company recovered from a destructive Iranian data-wiping attack. When asked what data was allegedly stolen, ShinyHunters claimed it exfiltrated data from Microsoft Entra, ServiceNow, SharePoint, Databricks, and Coupa, including internal documents, contracts, and customer information. The threat actor further claimed to have stolen more than 30 million rows of customer personally identifiable information (PII) from multiple datasets containing names, email addresses, phone numbers, physical addresses, dates of birth, and more than one million Social Security numbers. The group also claimed to have stolen over 22 million client notes containing doctor-patient conversations, more than 20 million medical orders, and customer agreements and NDAs. BleepingComputer has not independently verified the threat actor's claims regarding the stolen data. The second incident involves a threat actor known as ShadowByt3$, who contacted BleepingComputer claiming to have breached Abbott's Core Laboratory diagnostics business through its LabCentral customer portal. The threat actor said it breached the unit via its LabCentral customer portal using compromised customer credentials after identifying what it described as a "weak point" in the environment. According to the threat actor, they gained access on July 4, 2026, after which they slowly exfiltrated files by targeting API endpoints. ShadowByt3$ claims the stolen data includes CE manufacturing certificates, operation manuals, technical specifications, regulatory documentation, product requirement archives, calibrator value assignments, assay files, and other product documentation related to Abbott's laboratory diagnostic systems. The group says no customer data was stolen, but claims it obtained sensitive business documents and intellectual property. It also provided BleepingComputer with screenshots and a file listing as purported proof of the intrusion. Abbott confirmed to BleepingComputer that it is aware of the "potential" cyber incident but disputed the threat actor's characterization of the data it claims to have stolen, stating that all data stored in the environment is public and not sensitive. "LabCentral is an externally facing third-party hosted portal used by Abbott's core laboratory diagnostics business," an Abbott spokesperson told BleepingComputer. "It houses publicly available technical product reference documents, including operating manuals, troubleshooting checklists and product specifications, and does not contain proprietary/sensitive customer or business information." At this time, neither ShinyHunters nor ShadowByt3$ has publicly released data they claim to have stolen from Abbott.